GILEAD SCIENCES INC (GIS.DE) Stock Price & Overview
FRA:GIS • US3755581036
Current stock price
The current stock price of GIS.DE is 111.5 EUR. Today GIS.DE is down by -1.93%. In the past month the price decreased by -7.45%. In the past year, price increased by 23.34%.
GIS.DE Key Statistics
- Market Cap
- 138.396B
- P/E
- 16.00
- Fwd P/E
- 14.75
- EPS (TTM)
- 6.97
- Dividend Yield
- 2.37%
GIS.DE Stock Performance
GIS.DE Stock Chart
GIS.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GIS.DE. When comparing the yearly performance of all stocks, GIS.DE turns out to be only a medium performer in the overall market: it outperformed 58.17% of all stocks.
GIS.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to GIS.DE. Both the health and profitability get an excellent rating, making GIS.DE a very profitable company, without any liquidiy or solvency issues.
GIS.DE Earnings
On February 10, 2026 GIS.DE reported an EPS of 1.86 and a revenue of 7.92B. The company beat EPS expectations (0.73% surprise) and beat revenue expectations (0.98% surprise).
GIS.DE Forecast & Estimates
39 analysts have analysed GIS.DE and the average price target is 135.2 EUR. This implies a price increase of 21.26% is expected in the next year compared to the current price of 111.5.
For the next year, analysts expect an EPS growth of 8.48% and a revenue growth 3.45% for GIS.DE
GIS.DE Groups
Sector & Classification
GIS.DE Financial Highlights
Over the last trailing twelve months GIS.DE reported a non-GAAP Earnings per Share(EPS) of 6.97. The EPS increased by 76.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.9% | ||
| ROA | 14.42% | ||
| ROE | 37.49% | ||
| Debt/Equity | 0.97 |
GIS.DE Ownership
GIS.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.71 | 42.625B | ||
| 1AE | ARGENX SE | 28.77 | 42.6B | ||
| 22UA | BIONTECH SE-ADR | N/A | 23.126B | ||
| ABVX | ABIVAX SA | N/A | 7.766B | ||
| 2X1 | ABIVAX SA | N/A | 7.747B | ||
| GLPG | GALAPAGOS NV | N/A | 1.629B | ||
| GXE | GALAPAGOS NV | N/A | 1.628B | ||
| NANO | NANOBIOTIX | N/A | 1.392B | ||
| PHARM | PHARMING GROUP NV | 46.9 | 1.025B | ||
| PHGN | PHARMING GROUP NV | 47.13 | 1.021B | ||
| 6IV | INVENTIVA SA | N/A | 990.777M | ||
| IVA | INVENTIVA SA | N/A | 934.695M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 932.473M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About GIS.DE
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
Company Info
IPO: 1992-01-22
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA US
Employees: 17000
Phone: 13026587581
GILEAD SCIENCES INC / GIS.DE FAQ
What does GIS do?
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
What is the current price of GIS stock?
The current stock price of GIS.DE is 111.5 EUR. The price decreased by -1.93% in the last trading session.
What is the dividend status of GILEAD SCIENCES INC?
GILEAD SCIENCES INC (GIS.DE) has a dividend yield of 2.37%. The yearly dividend amount is currently 2.73.
What is the ChartMill technical and fundamental rating of GIS stock?
GIS.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
How is the market expecting GIS stock to perform?
39 analysts have analysed GIS.DE and the average price target is 135.2 EUR. This implies a price increase of 21.26% is expected in the next year compared to the current price of 111.5.
Is GILEAD SCIENCES INC (GIS.DE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GIS.DE.
Can you provide the market cap for GILEAD SCIENCES INC?
GILEAD SCIENCES INC (GIS.DE) has a market capitalization of 138.40B EUR. This makes GIS.DE a Large Cap stock.